Last reviewed · How we verify

Mochida Pharmaceutical Company, Ltd. — Portfolio Competitive Intelligence Brief

Mochida Pharmaceutical Company, Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Icosapent (MND-2119) Icosapent (MND-2119) phase 3 Omega-3 fatty acid / Triglyceride-lowering agent Multiple lipid metabolism pathways; FFAR1 (GPR40), FFAR4 (GPR120) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amarin Neuroscience Ltd · 1 shared drug class
  2. Yamaguchi University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mochida Pharmaceutical Company, Ltd.:

Cite this brief

Drug Landscape (2026). Mochida Pharmaceutical Company, Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mochida-pharmaceutical-company-ltd. Accessed 2026-05-17.

Related